Motretinide

Motretinide
Names

IUPAC name N-ethyl-9-(4-methoxy-2,3,6-trimethylphenyl)-3,7-dimethylnona-2,4,6,8-tetraenamide
Identifiers
ATC code	D10AD05
CAS Registry Number	54757-59-4^Y
ChemSpider	4880635
EC number	260-094-6
InChI InChI=1S/C23H31NO2/c1-8-24-23(25)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(26-7)20(6)19(21)5/h9-15H,8H2,1-7H3,(H,24,25)/b11-9+,13-12+,16-10+,17-14+ Key: IYIYMCASGKQOCZ-DJRRULDNSA-N InChI=1/C23H31NO2/c1-8-24-23(25)14-17(3)11-9-10-16(2)12-13-21-18(4)15-22(26-7)20(6)19(21)5/h9-15H,8H2,1-7H3,(H,24,25)/b11-9+,13-12+,16-10+,17-14+ Key: IYIYMCASGKQOCZ-DJRRULDNBU
Jmol-3D images	Image
KEGG	D05082
PubChem	6314185
SMILES CCNC(=O)/C=C(\C)/C=C/C=C(\C)/C=C/C1=C(C(=C(C=C1C)OC)C)C
Properties
Chemical formula	C₂₃H₃₁NO₂
Molar mass	353.49774
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
Y verify (what is: Y/N?)
Infobox references

Motretinide is an anti-acne preparation.^[1]

References

↑ Zouboulis, C. C. (2001). "Retinoids--which dermatological indications will benefit in the near future?". Skin pharmacology and applied skin physiology 14 (5): 303–315. PMID 11586072.

Acne-treating agents (D10)

Anti-inflammatory

Other

Combinations

^#WHO-EM
^‡Withdrawn from market
Clinical trials:
- ^†Phase III
- ^§Never to phase III

Index of skin appendages

Description	Anatomy Physiology Development

Disease	Congenital Neoplasms and cancer Other Symptoms and signs eponymous

Treatment	Procedures Acne drugs